A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).

Key facts

Study ID

NCT01230853

Run by

Eisai Inc.

People needed

80

Starts

2010-08-01

Expected to finish

2013-02-01

Last updated by the study team

2020-11-23

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Garden Grove, California, United States
• Study site — San Francisco, California, United States
• Study site — Orlando, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Eatontown, New Jersey, United States
• Study site — Princeton, New Jersey, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.